Use of ex vivo systems for biomarker discovery

Current Opinion in Pharmacology

Volumn 8, Issue 5, 2008, Pages 647-653

  LaVallie, Edward R ^a   Dorner, Andrew J ^a   Burczynski, Michael E ^b  

^a Discovery Biological Technologies   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; BONE MORPHOGENETIC PROTEIN; CD24 ANTIGEN; CHETOCIN; CYCLOPHOSPHAMIDE; CYTOCHROME P450; DEATH RECEPTOR 5; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; HERMES ANTIGEN; INTERLEUKIN 12; INTERLEUKIN 23; LAPATINIB; NEW DRUG; NOTCH RECEPTOR; PROTEIN INHIBITOR; SONIC HEDGEHOG PROTEIN; STA 5326; SYNDECAN 1; UNCLASSIFIED DRUG; WNT PROTEIN;

ADJUVANT THERAPY; BLOOD CULTURE; BREAST CANCER; CANCER CELL; CARTILAGE CELL; CELL CULTURE; CELL RENEWAL; CELL STRAIN HEPG2; DRUG MECHANISM; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG TARGETING; EX VIVO STUDY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENETIC ANALYSIS; GENETIC VARIABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN GENOME; IMMUNOASSAY; INDIVIDUALIZATION; LIVER TOXICITY; MASS SPECTROMETRY; MEDICAL DECISION MAKING; NICK END LABELING; PATIENT CARE; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SKIN BIOPSY; TREATMENT OUTCOME; TUMOR MODEL;

ANIMALS; BIOLOGICAL MARKERS; BLOOD CELLS; CARTILAGE; CELLS, CULTURED; CHONDROCYTES; DRUG RESISTANCE; DRUG THERAPY; HEPATOCYTES; HUMANS; SKIN;

EID: 54949157308     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2008.08.003     Document Type: Review

References (56)

1. Burczynski M.E., and Dorner A.J. Transcriptional profiling of peripheral blood cells in clinical pharmacogenomic studies. Pharmacogenomics 7 (2006) 187-202
2. Liew C.-C., Ma J., Tang H.-C., Zheng R., and Dempsey A.A. The peripheral blood transcriptome dynamically reflects system wide biology: a potential diagnostic tool. J Lab Clin Med 147 (2006) 126-132
3. Mohr S., and Liew C.-C. The peripheral-blood transcriptome: new insights into disease and risk assessment. Trends Mol Med 13 (2007) 422-432
4. Li L., Ying L., Naesens M., Xiao W., Sigdel T., Hsieh S., Martin J., Chen R., Liu K., Mindrinos M., et al. Interference of globin genes with biomarker discovery for allograft rejection in peripheral blood samples. Physiol Genomics 32 (2008) 190-197
5. Baker A.F., Landowski T., Dorr R., Tate W.R., Gard J.M.C., Tavenner B.E., Dragovich T., Coon A., and Powis G. The antitumor agent imexon activates antioxidant gene expression: evidence for an oxidative stress response. Clin Cancer Res 13 (2007) 3388-3394
6. Kantor A.B., Deng J., Waubant E., Lin H., Becker C.H., Lacy J.R., Perrone A.M., Bennett D., and Goelz S.E. Identification of short-term pharmacodynamic effects of interferon-beta-1a in multiple sclerosis subjects with broad-based phenotypic profiling. J Neuroimmunol 188 (2007) 103-116
7. Prync A., Yankilevich P., Barrero P., Bello R., Marangunich L., Vidal A., Criscuolo M., Benasayag L., Famulari A., Domínguez R., et al. Two recombinant human interferon-beta 1a pharmaceutical preparations produce a similar transcriptional response determined using whole genome microarray analysis. Int J Clin Pharmacol Ther 46 (2008) 64-71
8. Wada Y., Lu R., Zhou D., Chu J., Przewloka T., Zhang S., Li L., Wu Y., Qin J., Balasubramanyam V., et al. Selective abrogation of Th1 response by STA-5326, a potent IL-12/IL-23 inhibitor. Blood 109 (2007) 1156-1164
9. Sarker D., Pacey S., and Workman P. Use of pharmacokinetic/pharmacodynamic biomarkers to support rational cancer drug development. Biomark Med 1 (2007) 399-417. This review provides an excellent overview of need and processes for biomarkers in oncology drug development. It brings forward the type of plan needed for the validation of assays for clinical use.
10. Li A., Walling J., Kotliarov Y., Center A., Steed M.E., Ahn S.J., Rosenblum M., Mikkelsen T., Zenklusen J.C., and Fine H.A. Genomic changes and gene expression profiles reveal that established glioma cell lines are poorly representative of primary human gliomas. Mol Cancer Res 6 (2008) 21-30. Through SNP analysis and transcriptional profiling, chromosomal alterations, and differences in expression patterns indicative of altered biological pathways were detected between primary human gliomas and glioma cell lines. This study adds to the weight of evidence that cancer cell lines may not be relevant models for tumor biology.
11. van der Kuip H., Murdter T., Sonnenberg M., McClellan M., Gutzeit S., Gerteis A., Simon W., Fritz P., and Aulitzky W. Short term culture of breast cancer tissues to study the activity of the anticancer drug taxol in an intact tumor environment. BMC Cancer 6 (2006) 86
12. Estes J.M., Oliver P.G., Straughn J., Michael J., Zhou T., Wang W., Grizzle W.E., Alvarez R.D., Stockard C.R., LoBuglio A.F., et al. Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model. Gynecol Oncol 105 (2007) 291-298
13. Isham C.R., Tibodeau J.D., Jin W., Xu R., Timm M.M., and Bible K.C. Chaetocin: a promising new antimyeloma agent with in vitro and in vivo activity mediated via imposition of oxidative stress. Blood 109 (2007) 2579-2588. This study shows the power of performing ex vivo testing of drug candidates on primary cancer cells to support clinical testing and understand mechanism of cytotoxic effects.
14. Li X., Lewis M.T., Huang J., Gutierrez C., Osborne C.K., Wu M.-F., Hilsenbeck S.G., Pavlick A., Zhang X., Chamness G.C., et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100 (2008) 672-679
15. Potti A., Dressman H.K., Bild A., Riedel R.F., Chan G., Sayer R., Cragun J., Cottrill H., Kelley M.J., Petersen R., et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med 12 (2006) 1294-1300. Sophisticated transcriptional analysis identified regimen-specific gene expression signatures that predict tumor cell sensitivity to chemotherapeutics. Importantly, it includes validation with independent cell lines as well as published clinical data. This study suggests that while tumor cell lines are clearly biologically and genetically different than primary tumors, basic mechanisms may allow prediction of clinical responses and can be correlated to oncogenic pathways active in both cell culture and in vivo.
16. Bonnefoi H., Potti A., Delorenzi M., Mauriac L., Campone M., Tubiana-Hulin M., Petit T., Rouanet P., Jassem J., Blot E., et al. Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol 8 (2007) 1071-1078. An important study which shows that cancer cell line derived gene expression signatures can be applied to primary tumor expression signatures to accurately predict pateint response to therapy. Strikingly, single agent signatures could be combined to predict multiple agent therapeutic responses.
17. Isabel Lucena M., Garcia-Cortes M., Cueto R., Lopez-Duran J., and Andrade R.J. Assessment of drug-induced liver injury in clinical practice. Fundam Clin Pharmacol 22 (2008) 141-158
18. Turpeinen M., Ghiciuc C., Opritoui M., Tursas L., Pelkonen O., and Pasanen M. Predictive value of animal models for human cytochrome P450 (CYP)-mediated metabolism: a comparative study in vitro. Xenobiotica 37 (2007) 1367-1377
19. Westerink W.M., and Schoonen W.G. Cytochrome P450 enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells. Toxicol In Vitro 21 (2007) 1581-1591
20. Westerink W.M., and Schoonen W.G. Phase II enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells. Toxicol In Vitro 21 (2007) 1592-1602
21. DeCristofaro M.F., and Daniels K.K. Toxicogenomics in Biomarker Discovery. Methods Mol Biol 460 (2008) 185-194
22. Wetmore B.A., and Merrick B.A. Invited review: toxicoproteomics: proteomics applied to toxicology and pathology. Toxicol Pathol 32 (2004) 619-642
23. van Ravenzwaay B., Cunha G.C.-P., Leibold E., Looser R., Mellert W., Prokoudine A., Walk T., and Wiemer J. The use of metabolomics for the discovery of new biomarkers of effect. Toxicol Lett 172 (2007) 21-28
24. Collings F.B., and Vaidya V.S. Novel technologies for the discovery and quantitation of biomarkers of toxicity. Toxicology 245 (2008) 167-174
25. NCTR Research Accomplishments and Plans, FY2003-2004. U.S. Food and Drug Administration. National Center for Toxicological Research; 2004 (URL:http://www.fda.gov/nctr/science/03-04_Research_Plans/html/ofc_resea rch.html).
26. Guillouzo A., Corlu A., Aninat C., Glaise D., Morel F., and Guguen-Guillouzo C. The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. Chem Biol Interact 168 (2007) 66-73
27. Phillips R.L., and Sachs A.B. Skin biopsies for the measurement of clinical pharmacodynamic biomarkers. Curr Opin Biotechnol 16 (2005) 687-690
28. Camidge D.R., Pemberton M.N., Growcott J.W., Johnstone D., Laud P.J., Foster J.R., Randall K.J., and Hughes A.M. Assessing proliferation, cell-cycle arrest and apoptotic end points in human buccal punch biopsies for use as pharmacodynamic biomarkers in drug development. Br J Cancer 93 (2005) 208-215. An important study showing the feasibility of obtaining multiple skin biopsies from normal volunteers, and the suitability of these tissue specimens for the measurement of potential PD markers of cellular proliferation and apoptosis in oncology trials.
29. Jost M., Kari C., and Rodeck U. The EGF receptor - an essential regulator of multiple epidermal functions. Eur J Dermatol 10 (2000) 505-510
30. Alonso L., and Fuchs E. Stem cells in the skin: waste not, Wnt not. Genes Dev 17 (2003) 1189-1200
31. Lefort K., and Dotto G.P. Notch signaling in the integrated control of keratinocyte growth/differentiation and tumor suppression. Semin Cancer Biol 14 (2004) 374-386
32. Botchkarev V.A., and Sharov A.A. BMP signaling in the control of skin development and hair follicle growth. Differentiation 72 (2004) 512-526
33. Adolphe C., Narang M., Ellis T., Wicking C., Kaur P., and Wainwright B. An in vivo comparative study of sonic, desert and Indian hedgehog reveals that hedgehog pathway activity regulates epidermal stem cell homeostasis. Development 131 (2004) 5009-5019
34. Agulnik M., da Cunha Santos G., Hedley D., Nicklee T., dos Reis P.P., Ho J., Pond G.R., Chen H., Chen S., Shyr Y., et al. Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib. J Clin Oncol 25 (2007) 2184-2190. A significant study in which the investigators monitored the ability of erlotinib, a small-molecule EGFR tyrosine kinase inhibitor, to block autophosphorylation of EGFR in skin and in tumor biopsies and showed that the suppression of p-EGFR in skin with erlotinib treatment correlated with increased overall survival.
35. Folprecht G., Tabernero J., Kohne C.-H., Zacharchuk C., Paz-Ares L., Rojo F., Quinn S., Casado E., Salazar R., Abbas R., et al. Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with metastatic colorectal cancer. Clin Cancer Res 14 (2008) 215-223
36. Zinner R.G., Nemunaitis J., Eiseman I., Shin H.J.C., Olson S.C., Christensen J., Huang X., Lenehan P.F., Donato N.J., and Shin D.M. Phase I clinical and pharmacodynamic evaluation of oral CI-1033 in patients with refractory cancer. Clin Cancer Res 13 (2007) 3006-3014
37. Albanell J., Rojo F., Averbuch S., Feyereislova A., Mascaro J.M., Herbst R., LoRusso P., Rischin D., Sauleda S., Gee J., et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 20 (2002) 110-124
38. Baselga J., Albanell J., Ruiz A., Lluch A., Gascon P., Guillem V., Gonzalez S., Sauleda S., Marimon I., Tabernero J.M., et al. Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J Clin Oncol 23 (2005) 5323-5333
39. Herbst R.S., and Bunn Jr. P.A. Targeting the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res 9 (2003) 5813-5824
40. Prenzel N., Fischer O., Streit S., Hart S., and Ullrich A. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer 8 (2001) 11-31
41. Companjen A.R., van der Wel L.I., Wei L., Laman J.D., and Prens E.P. A modified ex vivo skin organ culture system for functional studies. Arch Dermatol Res 293 (2001) 184-190. This group built upon the pioneering organ culture development of Trowell et al. and showed that human skin biopsies could be cultured and proteins produced by the cultures could be assayed by ELISA and immunohistochemistry.
42. Trowell O.A. The culture of mature organs in a synthetic medium. Exp Cell Res 16 (1959) 118-147. Important early work in the development of cell culture methods that allowed in vitro experimentation on numerous mammalian tissue types.
43. Hellio M.P., Peschard M.J., Cohen C., Richard M., and Vignon E. Calcitonin inhibits phospholipase A2 and collagenase activity of human osteoarthritic chondrocytes. Osteoarthritis Cartilage 5 (1997) 121-128
44. Manning W.K., and Bonner Jr. W.M. Isolation and culture of chondrocytes from human adult articular cartilage. Arthritis Rheum 10 (1967) 235-239
45. Hauselmann H.J., Masuda K., Hunziker E.B., Neidhart M., Mok S.S., Michel B.A., and Thonar E.J. Adult human chondrocytes cultured in alginate form a matrix similar to native human articular cartilage. Am J Physiol 271 (1996) C742-752
46. Dingle J.T., Horsfield P., Fell H.B., and Barratt M.E. Breakdown of proteoglycan and collagen induced in pig articular cartilage in organ culture. Ann Rheum Dis 34 (1975) 303-311
47. von der Mark K., Gauss V., von der Mark H., and Muller P. Relationship between cell shape and type of collagen synthesised as chondrocytes lose their cartilage phenotype in culture. Nature 267 (1977) 531-532
48. Dahlberg L., Billinghurst R., Manner P., Nelson F., Webb G., Ionescu M., Reiner A., Tanzer M., Zukor D., Chen J., et al. Selective enhancement of collagenase-mediated cleavage of resident type II collagen in cultured osteoarthritic cartilage and arrest with a synthetic inhibitor that spares collagenase 1 (matrix metalloproteinase 1). Arthritis Rheum 43 (2000) 673-682
49. Zack M., Arner E., Anglin C., Alston J., Malfait A.-M., and Tortorella M. Identification of fibronectin neoepitopes present in human osteoarthritic cartilage. Arthritis Rheum 54 (2006) 2912-2922
50. Malfait A.-M., Liu R.-Q., Ijiri K., Komiya S., and Tortorella M.D. Inhibition of ADAM-TS4 and ADAM-TS5 prevents aggrecan degradation in osteoarthritic cartilage. J Biol Chem 277 (2002) 22201-22208
51. Wu J., Rush III T.S., Hotchandani R., Du X., Geck M., Collins E., Xu Z.-B., Skotnicki J., Levin J.I., and Lovering F.E. Identification of potent and selective MMP-13 inhibitors. Bioorg Med Chem Lett 15 (2005) 4105-4109
52. LaVallie E.R., Chockalingam P.S., Collins-Racie L.A., Freeman B.A., Keohan C.C., Leitges M., Dorner A.J., Morris E.A., Majumdar M.K., and Arai M. Protein kinase C{zeta} is up-regulated in osteoarthritic cartilage and is required for activation of NF-{kappa}B by tumor necrosis factor and interleukin-1 in articular chondrocytes. J Biol Chem 281 (2006) 24124-24137
53. Jones S.W., Brockbank S.M.V., Mobbs M.L., Good N.J.L., Soma-Haddrick S., Heuze A.J., Langham C.J., Timms D., Newham P., and Needham M.R.C. The orphan G-protein coupled receptor RDC1: evidence for a role in chondrocyte hypertrophy and articular cartilage matrix turnover. Osteoarthritis Cartilage/OARS, Osteoarthritis Res Soc 14 (2006) 597-608
54. Jeffrey J., and Aspden R. Cyclooxygenase inhibition lowers prostaglandin E2 release from articular cartilage and reduces apoptosis but not proteoglycan degradation following an impact load in vitro. Arthritis Res Ther 9 (2007) R129
55. Arai M., Anderson D., Kurdi Y., Annis-Freeman B., Shields K., Collins-Racie L.A., Corcoran C., DiBlasio-Smith E., Pittman D.D., Dorner A.J., et al. Effect of adenovirus-mediated overexpression of bovine ADAMTS-4 and human ADAMTS-5 in primary bovine articular chondrocyte pellet culture system. Osteoarthritis Cartilage 12 (2004) 599-613
56. Wyeth: A randomized, double-blind, placebo-controlled, multiple-dose regimen, parallel-group study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of AGG-523 administered orally to subjects with severe osteoarthritis. ClinicalTrials.gov Identifier NCT00454298; 2007. An innovative trial design that allowed access to proximal tissues (cartilage and synovial fluid) from severe OA patients undergoing joint replacement surgery following repeated oral dosing with an experimental aggrecanase inhibitor. PK/PD relationships could be established by measuring compound levels in the tissues and comparing to residual enzyme activity in cartilage explant cultures ex vivo.